SEC Filings
Filing date | Form | Description | View |
---|---|---|---|
SC 13G/A | An amendment to the SC 13G filing |
View HTML | |
10-K | Annual report which provides a comprehensive overview of the company for the past year |
View HTML EX-101.INS - EX-101.INS | |
10-K | Annual report which provides a comprehensive overview of the company for the past year |
View HTML EX-101.INS - EX-101.INS | |
10-K | Annual report which provides a comprehensive overview of the company for the past year |
View HTML EX-101.INS - EX-101.INS | |
10-K | Annual report which provides a comprehensive overview of the company for the past year |
View HTML EX-101.INS - EX-101.INS | |
10-K | Annual report which provides a comprehensive overview of the company for the past year |
View HTML EX-101.INS - EX-101.INS | |
10-K | Annual report which provides a comprehensive overview of the company for the past year |
View HTML EX-101.SCH - XBRL TAXONOMY EXTENSION SCHEMA | |
10-K | Annual report which provides a comprehensive overview of the company for the past year |
View HTML EX-101.SCH - XBRL TAXONOMY EXTENSION SCHEMA | |
10-K | Annual report which provides a comprehensive overview of the company for the past year |
View HTML EX-101.SCH - XBRL TAXONOMY EXTENSION SCHEMA | |
10-K | Annual report which provides a comprehensive overview of the company for the past year |
View HTML EX-101.SCH - XBRL TAXONOMY EXTENSION SCHEMA |
Data provided by Kaleidoscope.
For SEC filings prior to June 2, 2014, the date of the spin-off of Theravance Biopharma, Inc. from Theravance, Inc., please visit Innoviva, Inc.